Cargando…
1777P Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO MCBS
Autores principales: | Aboelhassan, R.A.M., Ali, M.H., Mohamed, A., Mosa, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506433/ http://dx.doi.org/10.1016/j.annonc.2020.08.1841 |
Ejemplares similares
-
ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019) -
Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017) -
Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021) -
PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023) -
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)